AbbVie said its Phase III drug risankizumab is more effective than its own blockbuster drug Humira or J&J's Stelara for psoriasis patients. Source: BioSpace

BlueRock Therapeutics established its corporate headquarters in Cambridge, MA and has appointed two additional senior executive staffers. Source: BioSpace

BioMarin announced that the FDA granted its valoctocogene roxaparvovec for Hemophilia A Breakthrough Therapy Designation. Source: BioSpace

Stryker picked up controlling interest in Vexim, a French medical device company that specializes in the minimally invasive treatment of vertebral fractures. Source: BioSpace

Finding a treatment for Sanfilippo Syndrome is a personal matter for the Lysogene team. Source: BioSpace

The former Biogen CEO is making waves at his new venture, Vir Biotechnology. Source: BioSpace

Ablynx announced the price of its U.S. IPO at $17.50. Source: BioSpace

In addition to the layoffs, the company is also looking to divest its Infectious Disease Business. Source: BioSpace

Biogen released its third-quarter financials yesterday, showing total revenues of $3.1B for the quarter, a 4 percent gain compared to the same period the previous year. Source: BioSpace

Corbus' stock popped on the release of topline results from a midstage study involving its lead (and only) clinical drug, anabasum. Source: BioSpace